News center More...

10 2024-11
University-Industry Integration | Gluetacs Successfully Selected for Lingang New Area College Student Internship Base List
06 2024-11
Meeting at the CIIE | Gluetacs Highlights at the 7th China International Import Expo
01 2024-11
Gluetacs jointly reported the mechanism of SOS1 degrader overcoming KRAS mutation and BCR-ABL-positive CML resistance in Cancer Research
24 2024-09
GLUETACS co-published a research paper on BCL-xL degrader displaying synergistic antitumor effects on hepatocellular carcinoma
11 2024-09
Gluetacs Therapeutics was selected for the Huayi 2024 China Biopharmaceutical Technology Innovation Value List Top 10 Small Molecule Innovative Drug Companies with the Most Growing Potential
16 2024-07
Linkage between government and enterprise, Biologic won the “Service package” of key enterprises in Lingang New Area in 2024
21 2024-06
Gluetacs Co-publishes Cover Article in CELL Sub-Journal Reporting NAMPT-targeting PROTAC and nicotinic acid co-administration elicit safe and robust anti-tumor efficacy in NAPRT-deficient pan-cancers